PEDIATRIC IMMUNOLOGY ENROLLMENT FORM

KLOUDSCRIPT
Community Led Specialty Pharmacy Care

❶ PATIENT INFORMATION:

Name: ____________________
Address: ____________________
City: __________ State: ____ Zip: ______
Phone: __________ Alt. Phone: __________
Email: ____________________
DOB: ______ Gender: ❍ M ❍ F Caregiver: ______
Height: ______ Weight: ______ Allergies: ______

❷ PRESCRIBER INFORMATION:

Name: ____________________
Address: ____________________
City: __________ State: ____ Zip: ______
Phone: __________ Fax: __________
NPI: __________ DEA: __________
Tax I.D.: ____________________
Office Contact: __________ Phone: __________

v10.3_062623
© 2020 KloudScript, Inc. - All rights reserved.

❸ STATEMENT OF MEDICAL NECESSITY: (Please Attach All Medical Documentation)

Date of Diagnosis: __________
ICD-10: __________ Other: __________
TB Test: ❑ Positive ❑ Negative Date: ______
LFT: ALT: ______ AST: ______ Date: ______
Assessment: ❑ Moderate ❑ Mod to Severe ❑ Severe
_____% BSA affected
❑ Scalp ❑ Face ❑ Chest ❑ Arms ❑ Hands ❑ Nails
❑ Back ❑ Groin ❑ Buttocks ❑ Legs ❑ Other: _____
❑ ISGA or ❑ EASI __________

Patient also taking Methotrexate? ❑ Yes ❑ No
Serious or active infection present? ❑ Yes ❑ No
Hep B and Hep C ruled out or treatment started? ❑ Yes ❑ No
Does patient have latex allergy? ❑ Yes ❑ No

If Prior Authorization is denied, recommended formulary alternatives will be provided to the prescriber based upon the patient's insurance coverage.

Prior Failed Treatments:	Indicate Drug Name and Length of Treatment:
❑ 5-ASA	______
❑ Biologics	______
❑ Corticosteroids	______
❑ Immunosuppressants	______
❑ Methotrexate	______
❑ NSAIDS	______
❑ Surgery	______
❑ Topical/Oral Antibiotics	______
❑ UVA ❑ UVB	______
❑ Others	______

❹ INJECTION TRAINING:
❍ To Be Administered by Pharmacist (State of Missouri Only) ❍ Pharmacist to Provide Training ❍ Patient Trained in MD Office ❍ Manufacturer Nurse Support

❺ PICK UP OR DELIVERY:
❍ Delivery to Patient’s Home ❍ Delivery to Physician’s Office ❍ Pharmacy to Coordinate

❻ INSURANCE INFORMATION: Please Include Front and Back Copies of Pharmacy and Medical Card

PRESCRIPTION INFORMATION: (Please be sure to choose both induction and maintenance dose where applicable)

Patient Name: ____________________ Patient's Date of Birth: __________

Medication	Dosage & Strength	Direction	QTY	Refills
❑ AMJEVITA™	❑ 10mg/0.2ml Prefilled Syringe ❑ 20mg/0.4ml Prefilled Syringe ❑ 40mg/0.8ml Prefilled Syringe ❑ 40mg/0.8ml Pen	**Juvenile Idiopathic Arthritis (2 years of age and older)** ❑ **10kg to <15kg:** Inject 10mg every other week ❑ **15kg to <30kg:** Inject 20mg every other week ❑ **≥30kg:** Inject 40mg every other week	2	
		Crohn's Disease (6 years of age and older): ❑ **Induction Dose:** ❑ **17kg to <40kg:** Inject 80mg on day 1 and 40mg day 15	3	
		❑ ≥40kg: Inject 160mg (single-dose or split over two consecutive days) on day 1 and 80mg day 15	6	
		Maintenance Dose: ❑ **17kg to <40kg:** Inject 80mg on day 1 and 40mg day 15	3	
		❑ ≥40kg: Inject 160mg (single-dose or split over two consecutive days) on day 1 and 80mg day 15	6	
❑ COSENTYX®	❑ 150mg/ml single-dose Sensoready® Pen ❑ 150mg/ml single-dose Prefilled Syringe ❑ 75mg/0.5ml single-dose Prefilled Syringe ❑ 300mg/2ml single-dose UnoReady pen ❑ 300mg/2ml single-dose prefilled Syringe ❑ For Healthcare Professional Use Only: 150mg lyophilized powder in a single-dose vial for reconstitution	**PsO pediatric patients 6 years and older:** ❑ <50kg: 75mg at week 0, 1, 2, 3, and 4 and every 4 weeks thereafter ❑ ≥50kg: 150mg at week 0, 1, 2, 3, and 4 and every 4 weeks thereafter		
		PsA pediatric patients 2 years and older: ❑ ≥15kg and <50kg: 75mg at week 0, 1, 2, 3, and 4 and every 4 weeks thereafter ❑ ≥50kg: 150mg at week 0, 1, 2, 3, and 4 and every 4 weeks thereafter		
		Enthesitis-Related Arthritis 4 years and older: ❑ ≥15kg and <50kg: 75mg at weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter ❑ ≥50kg: 150mg at week 0, 1, 2, 3, and 4 and every 4 weeks thereafter		
❑ DUPIXENT®	**Pediatric Atopic Dermatitis (6 months to 17 years of age):** ❑ 300mg/2ml single-dose Prefilled Syringe ❑ 200mg/1.14ml single-dose Prefilled Syringe ❑ 300mg/2ml single-dose Prefilled Pen ❑ 200mg/1.14ml single-dose Prefilled Pen	❑ **Induction Dose:** ❑ **≥60kg:** Inject 600mg SC (two 300mg injections) ❑ **30 to <60kg:** Inject 400mg SC (two 200mg injections) ❑ **15 to <30kg:** Inject 600mg SC (two 300mg injections)	2	0
		❑ **Maintenance Dose:** ❑ **≥60kg:** Inject 300mg SC every other week ❑ **30 to <60kg:** Inject 200mg SC every other week ❑ **15 to <30kg:** Inject 300mg SC every 4 weeks		
		❑ **Pediatric patients 6 months to 5 years of age:** ❑ 5 to <15kg: 200mg (one 200mg injection) every 4 weeks ❑ 15 to <30kg: 300mg (one 300mg injection) every 4 weeks		
❑ EUCRISA®	**Pediatric patients 3 months of age and older:** ❑ 2% Ointment	❑ Apply a thin layer twice daily on affected area	60g 100g	0
❑ ENBREL®	❑ 50mg/ml Sureclick® Autoinjector ❑ 50mg/ml Enbrel Mini® Prefilled Cartridge For Enbrel Mini® only: AutoTouch® reusable Autoinjector ❑ 50mg/ml Prefilled Syringe ❑ 25mg/0.5ml Prefilled Syringe ❑ 25mg Lyophilized Power Vial ❑ Other: __________	**Plaque Psoriasis + Polyarticular Juvenile Idiopathic Arthritis Weight-Based Dosing** ❑ ≥63kg: Inject 50mg weekly ❑ <63kg: Inject 0.8mg/kg weekly (maximum 50mg/week) (To achieve pediatric doses other than 50mg or 25mg, use reconstituted Enbrel lyophilized powder)		
❑ ______	__________	__________		

PRESCRIBER SIGNATURE:
I authorize pharmacy to act as my designee for initiating and coordinating insurance prior authorizations, nursing services and patient assistance programs.

Signature: ____________ Date: ______ Signature: ____________ Date: ______

Substitution Permitted **Dispense As Written**

Prior authorization approval and insurance benefits will be determined by the payor based upon the patient’s eligibility, medical necessity, and the terms of the patient’s coverage, among other things. Participation in this program is not a guarantee of prior authorization or of payment.

Confidentiality Notice: This fax is intended to be delivered only to the named addressee and contains confidential information that may be protected health information under federal and state laws. If you are not the named addressee, you should not disseminate, distribute or copy this fax. Please inform the sender immediately if you have received this document in error and then destroy this document immediately.

Lorem ipsum

PEDIATRIC IMMUNOLOGY ENROLLMENT FORM

❶ PATIENT INFORMATION:

Name: ______________________________

Address: ______________________________

City: ____________ State: ____ Zip: ________

Phone: ____________ Alt. Phone: ____________

Email: ______________________________

DOB: ________ Gender: ❍ M ❍ F Caregiver: ________

Height: ______ Weight: ______ Allergies: __________

❷ PRESCRIBER INFORMATION:

Name: ______________________________

Address: ______________________________

City: ____________ State: ____ Zip: ________

Phone: ____________ Fax: ____________

NPI: ____________ DEA: ____________

Tax I.D.: ______________________________

Office Contact: ____________ Phone: ____________

v10.3_062623

❸ STATEMENT OF MEDICAL NECESSITY: (Please Attach All Medical Documentation)

Date of Diagnosis: ____________________

ICD-10: ____________ Other: ____________

TB Test: ❑ Positive ❑ Negative Date: ________

LFT: ALT: ________ AST: ________ Date: ________

Assessment: ❑ Moderate ❑ Mod to Severe ❑ Severe

_____% BSA affected

❑ Scalp ❑ Face ❑ Chest ❑ Arms ❑ Hands ❑ Nails

❑ Back ❑ Groin ❑ Buttocks ❑ Legs ❑ Other: _____

❑ ISGA or ❑ EASI ____________________

Patient also taking Methotrexate? ❑ Yes ❑ No

Serious or active infection present? ❑ Yes ❑ No

Hep B and Hep C ruled out or treatment started? ❑ Yes ❑ No

Does patient have latex allergy? ❑ Yes ❑ No

If Prior Authorization is denied, recommended formulary alternatives will be provided to the prescriber based upon the patient's insurance coverage.

Prior Failed Treatments:	Indicate Drug Name and Length of Treatment:
❑ 5-ASA	____________
❑ Biologics	____________
❑ Corticosteroids	____________
❑ Immunosuppressants	____________
❑ Methotrexate	____________
❑ NSAIDS	____________
❑ Surgery	____________
❑ Topical/Oral Antibiotics	____________
❑ UVA ❑ UVB	____________
❑ Others	____________

❹ INJECTION TRAINING:

❍ To Be Administered by Pharmacist (State of Missouri Only) ❍ Pharmacist to Provide Training ❍ Patient Trained in MD Office ❍ Manufacturer Nurse Support

❺ PICK UP OR DELIVERY:

❍ Delivery to Patient's Home ❍ Delivery to Physician's Office ❍ Pharmacy to Coordinate

❻ INSURANCE INFORMATION: Please Include Front and Back Copies of Pharmacy and Medical Card

© 2020 KloudScript, Inc. - All rights reserved.

PRESCRIPTION INFORMATION: (Please be sure to choose both induction and maintenance dose where applicable)

Patient Name: ______________________________ Patient's Date of Birth: ____________

Medication	Dosage & Strength	Direction	QTY	Refills
❑ HUMIRA®	**Hidradenitis Suppurativa** ❑ Adolescent Hidradenitis Suppurativa 80mg/0.8ml and 40mg/0.4ml Starter pack ❑ Adolescent Hidradenitis Suppurativa 40mg/0.4ml Starter Package ❑ Adolescent Hidradenitis Suppurativa 40mg/0.8ml Starter Package ❑ 40mg/0.4ml Pen ❑ 40mg/0.8ml Pen ❑ 80mg/0.8ml Pen ❑ 40mg/0.4ml Prefilled Syringe ❑ 40mg/0.8ml Prefilled Syringe ❑ 80mg/0.8ml Prefilled Syringe	❑ **Induction Dose (Adolescents 12 years and older):** ❑ **30kg to <60kg:** Inject 80mg SC on day 1, then 40mg SC on day 8 and every other week thereafter ❑ **≥60kg:** Inject two 80mg pens SC on day 1, then one 80mg pen SC on day 15 ❑ **≥60kg:** Inject one 80mg pen SC on day 1, then 80mg pen SC on day 2, then one 80mg pen SC on day 15		
		❑ **Maintenance Dose (Adolescents 12 years and older):** ❑ **30kg to <60kg:** Inject 40mg every other week ❑ **≥60kg:** Inject 40mg on day 29 then Inject 40mg every week ❑ **≥60kg:** Inject 80mg on day 29 then Inject 80mg every other week		
❑ HUMIRA®	**Juvenile Idiopathic Arthritis + Pediatric Uveitis** ❑ 10mg/0.1ml Prefilled Syringe ❑ 10mg/0.2ml Prefilled Syringe ❑ 20mg/0.2ml Prefilled Syringe ❑ 20mg/0.4ml Prefilled Syringe ❑ 40mg/0.4ml Prefilled Syringe ❑ 40mg/0.8ml Prefilled Syringe ❑ 40mg/0.4ml Pen ❑ 40mg/0.8ml Pen	❑ **Weight-Based Dosing (5 years and older):** ❑ **10kg to <15kg:** Inject 10mg SC every other week ❑ **15kg to <30kg:** Inject 20mg SC every other week ❑ **≥30kg:** Inject 40mg SC every other week		
❑ HUMIRA®	**Pediatric Crohn's Disease** ❑ **Pediatric Crohn's Starter Pack Prefilled Syringe:** ❑ 80mg/0.8ml, 40mg/0.4ml ❑ 40mg/0.8ml ❑ 80mg/0.8ml ❑ **Maintenance pack** ❑ 20mg/0.2ml Prefilled Syringe ❑ 20mg/0.4ml Prefilled Syringe ❑ 40mg/0.4ml Pen ❑ 40mg/0.4ml Prefilled Syringe	❑ **Induction Dose (Pediatrics patients 6 years and older):** ❑ **17kg to <40kg:** Inject one 80mg pen SC on day 1, then one 40mg pen SC on day 15	2	0
		❑ **≥40kg:** Inject two 80mg pens SC on day 1, then one 80mg pen SC on day 15 ❑ **≥40kg:** Inject one 80mg pen SC on day 1, then 80mg pen SC on day 2, then one 80mg pen SC on day 15	3	0
		❑ **Maintenance Dose (Pediatrics patients 6 years and older):** ❑ **17kg to <40kg:** Inject 20mg SC every other week ❑ **≥40kg:** Inject 40mg SC every other week	2	
	All strengths and dosages listed are Humira® Citrate Free			
❑ HUMIRA®	**Pediatric Ulcerative Colitis** ❑ Pediatric Ulcerative Colitis' Starter Pack: 80mg/0.8ml Pen ❑ 20mg/0.2ml Prefilled Syringe ❑ 20mg/0.4ml Prefilled Syringe ❑ 40mg/0.4ml Pen ❑ 40mg/0.8ml Pen ❑ 80mg/0.8ml Pen ❑ 40mg/0.4ml Prefilled Syringe ❑ 40mg/0.8ml Prefilled Syringe ❑ 80mg/0.8ml Prefilled Syringe	❑ **Induction Dose (5 years and older):** ❑ **20kg to 40kg:** Inject 80mg SC at week 0 (day 1), then 40mg SC at week 1 (day 8), then 40mg SC at week 2 (day 15) ❑ **>40kg:** Inject 160mg SC at week 0 (day 1), then 80mg SC at week 1 (day 8), then 40mg SC at week 2 (day 15)		
		❑ **Maintenance Dose (Pediatric patients 5 years and older):** ❑ **20kg to 40kg:** Inject 40mg SC at week 4 (day 29) and every other week thereafter ❑ **20kg to 40kg:** Inject 20mg SC at week 4 (day 29) and every other week thereafter ❑ **40kg:** Inject 80mg SC at week 4 (day 29) and every other week thereafter ❑ **40kg:** Inject 40mg SC at week 4 (day 29) and every other week thereafter		
❑ ________	____________	____________________		

PRESCRIBER SIGNATURE: I authorize pharmacy to act as my designee for initiating and coordinating insurance prior authorizations, nursing services and patient assistance programs.

Signature: ____________________ Date: ________
Substitution Permitted

Signature: ____________________ Date: ________
Dispense As Written

Prior authorization approval and insurance benefits will be determined by the payor based upon the patient's eligibility, medical necessity, and the terms of the patient's coverage, among other things. Participation in this program is not a guarantee of prior authorization or of payment.

Confidentiality Notice: This fax is intended to be delivered only to the named addressee and contains confidential information that may be protected health information under federal and state laws. If you are not the named addressee, you should not disseminate, distribute or copy this fax. Please inform the sender immediately if you have received this document in error and then destroy this document immediately.

PEDIATRIC IMMUNOLOGY ENROLLMENT FORM

KLOUDSCRIPT
Community Led Specialty Pharmacy Care

1 PATIENT INFORMATION:

Name: ______
Address: ______
City: ______ State: ____ Zip: ______
Phone: ______ Alt. Phone: ______
Email: ______
DOB: ______ Gender: ❍ M ❍ F Caregiver: ______
Height: ______ Weight: ______ Allergies: ______

2 PRESCRIBER INFORMATION:

Name: ______
Address: ______
City: ______ State: ____ Zip: ______
Phone: ______ Fax: ______
NPI: ______ DEA: ______
Tax I.D.: ______
Office Contact: ______ Phone: ______

3 STATEMENT OF MEDICAL NECESSITY: (Please Attach All Medical Documentation)

Date of Diagnosis: ______
ICD-10: ______ Other: ______
TB Test: ❑ Positive ❑ Negative Date: ______
LFT: ALT: ______ AST: ______ Date: ______
Assessment: ❑ Moderate ❑ Mod to Severe ❑ Severe
_____% BSA affected
❑ Scalp ❑ Face ❑ Chest ❑ Arms ❑ Hands ❑ Nails
❑ Back ❑ Groin ❑ Buttocks ❑ Legs ❑ Other: ______
❑ ISGA or ❑ EASI ______

Patient also taking Methotrexate? ❑ Yes ❑ No
Serious or active infection present? ❑ Yes ❑ No
Hep B and Hep C ruled out or treatment started? ❑ Yes ❑ No
Does patient have latex allergy? ❑ Yes ❑ No

If Prior Authorization is denied, recommended formulary alternatives will be provided to the prescriber based upon the patient's insurance coverage.

Prior Failed Treatments:	Indicate Drug Name and Length of Treatment:
❑ 5-ASA	______
❑ Biologics	______
❑ Corticosteroids	______
❑ Immunosuppressants	______
❑ Methotrexate	______
❑ NSAIDS	______
❑ Surgery	______
❑ Topical/Oral Antibiotics	______
❑ UVA ❑ UVB	______
❑ Others	______

4 INJECTION TRAINING:
❍ To Be Administered by Pharmacist (State of Missouri Only) ❍ Pharmacist to Provide Training ❍ Patient Trained in MD Office ❍ Manufacturer Nurse Support

5 PICK UP OR DELIVERY:
❍ Delivery to Patient's Home ❍ Delivery to Physician's Office ❍ Pharmacy to Coordinate

6 INSURANCE INFORMATION: Please Include Front and Back Copies of Pharmacy and Medical Card

PRESCRIPTION INFORMATION: (Please be sure to choose both induction and maintenance dose where applicable)

Patient Name: ______ Patient's Date of Birth: ______

Medication	Dosage & Strength	Direction	QTY	Refills
❑ HUMIRA® Biosimllar	❑ ______	❑ ______		
❑ OPZELURA™	**12 years of age and older:** ❑ 1.5% Cream	❑ Apply a thin layer twice daily to affected areas *Do not use more than 60 grams per week*	60g	
❑ RINVOQ® XR	❑ 15mg ER Tablet ❑ 30mg ER Tablet	❑ **Pediatric patients 12 years of age and older weighing at least 40kg:** ❑ Take 15mg tablet once daily **"If an adequate response is not achieved, consider increasing the dosage to 30mg orally once daily"**	30	
❑ STELARA®	❑ 45mg/0.5ml Prefilled Syringe ❑ 45mg/0.5ml Single-Dose Vial ❑ 90mg/ml Prefilled Syringe	**Psoriasis Pediatric Dose (6 to 17 years old):**		
		❑ <60kg: Inject 0.75mg/kg SC initially at 4 weeks, then every 12 weeks thereafter		0
		❑ 60kg to 100kg: Inject 45mg SC initially at 4 weeks, then every 12 weeks thereafter	1	0
		❑ >100kg: Inject 90mg SC initially at 4 weeks, then every 12 weeks thereafter		0
		Psoriatic Arthritis Pediatric Dose (6 to 17 years old): ❑ <60kg: Inject 0.75mg/kg SC initially at 4 weeks, then every 12 weeks thereafter ❑ >60kg: Inject 45mg SC initially at 4 weeks, then every 12 weeks thereafter ❑ >100kg with co-existent moderate-to-severe plaque psoriasis: Inject 90mg SC initially at 4 weeks, then every 12 weeks thereafter		
❑ TALTZ®	**Pediatric Plaque Psoriasis** ❑ 80mg/ml Single-Dose Prefilled Autoinjector ❑ 80mg/ml Single-Dose Prefilled Syringe	❑ **Induction Dose (6 years and older):** ❑ >50kg: Inject 160mg SC (two 80mg injections) at week 0	2	0
		❑ 25 to 50kg: Inject 80 mg SC at week 0 ❑ <25kg: Inject 40mg SC at week 0	1	
		❑ **Maintenance Dose (6 years and older):** ❑ **>50kg:** Inject 80mg SC at week 4 and every 4 weeks thereafter ❑ **25 to 50kg:** Inject 40 mg SC at week 4 and every 4 weeks thereafter ❑ **<25kg:** Inject 20 mg at week 4 and every 4 weeks thereafter		
	20mg and 40mg doses for patients weighing ≤50kg must be prepared and administered by a qualified healthcare professional.			
❑ XELJANZ®	**Polyarticular Course Juvenile Idiopathic Arthritis (pcJIA)** ❑ 1mg/ml oral solution	❑ **Weight-Based Dosing (Pediatric patients 2 years and older):** ❑ **10kg to <20kg:** Take 3.2mg (3.2ml oral solution) twice daily ❑ **20kg to <40kg:** Take 4mg (4ml oral solution) twice daily ❑ **≥40kg:** Take 5mg (one 5mg oral tablet or 5ml oral solution) twice daily	60	
	❑ 5mg tablets	❑ Take 5mg by mouth twice daily		
❑ YUSIMRY™	**Juvenile Idiopathic Arthritis + Pediatric Crohn's Disease** ❑ 40mg/0.8ml Prefilled Syringe ❑ 40mg/0.8ml Prefilled Pen	**Juvenile idiopathic arthritis pediatric patients 2 years of age and older >30kg:** ❑ Inject 40mg SC every other week	2	
		CD pediatric patients 6 years of age and older >40kg: ❑ **Induction Dose:** Inject 160mg SC on day 1 and 80mg on day 15	6	
		❑ **Maintenance Dose:** Inject 40mg SC every other week (Starting on Day 29)	2	
❑ ______	______	______		

PRESCRIBER SIGNATURE: I authorize pharmacy to act as my designee for initiating and coordinating insurance prior authorizations, nursing services and patient assistance programs.

Signature: ______ Date: ______
Substitution Permitted

Signature: ______ Date: ______
Dispense As Written

Prior authorization approval and insurance benefits will be determined by the payor based upon the patient's eligibility, medical necessity, and the terms of the patient's coverage, among other things. Participation in this program is not a guarantee of prior authorization or of payment.

Confidentiality Notice: This fax is intended to be delivered only to the named addressee and contains confidential information that may be protected health information under federal and state laws. If you are not the named addressee, you should not disseminate, distribute or copy this fax. Please inform the sender immediately if you have received this document in error and then destroy this document immediately.

© 2020 KloudScript, Inc. - All rights reserved. v10.3_062623